Future mRNA vaccines may prevent food and seasonal allergies
Early research from Penn Medicine finds a new mRNA vaccine stops allergens from causing immune reactions and life-threatening inflammation, with promise for future treatment for a variety of seasonal and food allergies.
2 min. read
A new mRNA vaccine has stopped allergens from causing dangerous immune reactions and life-threatening inflammation in mice, according to researchers from the Perelman School of Medicine and Cincinnati Children’s. The vaccine may one day be tested for tailoring to a variety of seasonal and food allergies. The study is published in the Journal of Clinical Investigation.
“This is a potential breakthrough for millions of people worldwide who suffer from life-threatening allergies,” says Nobel laureate Drew Weissman, the Roberts Family Professor in Vaccine Research at Penn Medicine and co-lead of the study.
Weissman, along with Jilian Melamed, an assistant professor of infectious diseases, Mohamad-Gabriel Alameh,an assistant professor of pathology and laboratory medicine, and others at Cincinnati Children’s modeled this new vaccine on the design of the COVID-19 mRNA lipid nanoparticle (LNP) vaccines.
This time, however, scientists tweaked the mRNA to instruct cells to produce proteins that resemble certain allergens. By presenting these proteins in a controlled way, the vaccine didn’t cause allergic reactions but did instruct the immune system to respond more appropriately in the future. And, when mice were later exposed to the respective allergens, the vaccines worked.
“People with food allergies that can cause anaphylactic shock are rightfully fearful in social situations, eating out in public, sharing food, and engaging in other fun activities where there are food and allergens around,” says Weissman. “Allowing people to partake in foods they were never able to eat would be incredibly rewarding, but I’ll even be happy if we can one day introduce a vaccine that allows parents to breathe just a little easier when sending their kids to class birthday parties.”
Penn physicists led by Bo Zhen have created hybrid light-matter particles that interact strongly enough to compute, pointing toward ultrafast, low-energy optical AI hardware.
Penn’s newest supercomputer is transforming research
Penn’s first campus-wide HPC and AI cluster, “Betty,” is expanding access to powerful computing, enabling groundbreaking projects, and fostering new collaborations across disciplines.
A bioengineered bean gum from the lab of Penn Dental’s Henry Daniell is found to reduce the levels of three microbes associated with head and neck squamous cell cancer to almost zero, without affecting the beneficial bacteria normally found in the mouth.
Fighting oral cancer with bioengineered chewing gum
Research led by Penn Dental’s Henry Daniell shows that antiviral and antibacterial chewing gums reduce the levels of three microbes linked to worse outcomes in oral cancers, paving the way for more effective and affordable therapies.
The performing arts at Penn: Process, practice, and purpose
In the vivid tapestry of performing arts groups at Penn, students prepare for their performances while simultaneously enriching their college experience.
